UCB :: The next generation biopharma leader

Welcome to one UCB

UCB, Inc., with headquarters in Atlanta, Ga., is a wholly owned subsidiary and U.S. affiliate of
UCB S.A.

UCB, Brussels, Belgium, is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders.

Latest news

UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.29-January-2010 | pdf file, 78 kb
UCB Commemorates Epilepsy Awareness Month with New and Enhanced Patient-Centered Initiatives02-November-2009 | pdf file, 96 kb
FDA approves Xyzal® for use in children age six months and older for the relief of perennial allergic rhinitis and chronic idiopathic urticaria24-August-2009 |pdf file, 53 kb
UCB and Crohn’s disease working group award $175,000 in research grants to gastroenterology fellows1-June-2009 |pdf file, 62 kb
CIMZIA®(certolizumab pegol) provides long-term remission and response rates in Infliximab-refractory Crohn’s patients31-May-2009 |pdf file, 153 kb

More newsLorem

Patients

Patients are at the heart of everything we do at UCB, Inc.

lorem

Journalists

UCB is in the news. For more information, click here.

lorem

Job Seekers

Join us and make a world of difference as we build the next generation biopharma, supported by a dynamic team in the U.S. and abroad.

lorem

About UCB in the U.S.

For more information about UCB in the U.S., click here.

lorem